Back

Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial

31 August 2026 (12:24 - 12:36)
Organised by: Logo
Congress Presentation Part of: Lipids and myocardial infarction Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Fangfang Wang

Peking University Third Hospital, Beijing (China)

4 More presentations in this session

Presentation thumbnail
Lipoprotein(a), smoking, and diabetes are additive, but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome: An analysis of the ODYSSEY OUTCOMES trial
Professor G. Schwartz (Aurora, US)
Abstract Slides
Presentation thumbnail
Sex differences in lipid management among high-risk patients without prior myocardial infarction or stroke: results from the VESALIUS-REAL global study
Associate Professor E. Hagstrom (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Extreme HDL-C associated increased mortality is explained by confounding due to progressively increasing alcohol-induced multisystem morbidity
Doctor B. Ference (Cambridge, GB)
Abstract Slides
Presentation thumbnail
FH genotype stratifies LDL-C–lowering response and improves diagnostic discrimination in severe hypercholesterolemia
Doctor J. Bernhard (Vienna, AT)
Abstract Slides

Access the full session

Session thumbnail
Lipids and myocardial infarction
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 12:24 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of inclisiran monotherapy in patients with hypercholesterolemia without background lipid-lowering therapy: a systematic review and meta-analysis
24 April 2026
thumbnail
Congress Presentation
SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study
1 September 2024
thumbnail
Congress Presentation
Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial
1 September 2025
thumbnail
Congress Presentation
RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency
31 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources